Nucleic acids

The Oligonucleotide Therapeutics Society Presents the 2021 Virtual Conference

Retrieved on: 
Saturday, September 4, 2021
Nucleic acids, Branches of biology, Biology, RNA, Molecular biology, Small interfering RNA, Silence Therapeutics, RNA interference, Alnylam Pharmaceuticals, Sense, Intellia Therapeutics

SAN DIEGO, Sept. 04, 2021 (GLOBE NEWSWIRE) -- The Oligo Meeting is purposefully designed to bring people together to share incredible advancements in the field of oligonucleotide therapeutics.

Key Points: 
  • SAN DIEGO, Sept. 04, 2021 (GLOBE NEWSWIRE) -- The Oligo Meeting is purposefully designed to bring people together to share incredible advancements in the field of oligonucleotide therapeutics.
  • Last year's virtual meeting was extraordinarily successful, and this year's virtual conference has been carefully planned to be even more seamlessly engaging and productive.
  • Recorded talks and posters can be viewed on-demand through December 31, 2021, for all registered delegates.
  • Last year's virtual conference received rave reviews from participants and this year's virtual meeting is expected to be even more spectacular.

Exicure, Inc. to Present at the BTIG Virtual Biotechnology Conference

Retrieved on: 
Wednesday, August 4, 2021
Biotechnology, Health, Genetics, Clinical Trials, Oncology, Nucleic acids, Spherical nucleic acid, SNA, Biotechnology, Natural sciences

Exicure , Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) technology, today announced that CEO David Giljohann will present at the BTIG Virtual Biotechnology Conference on Monday, August 9, 2021 at 2:30pm ET.

Key Points: 
  • Exicure , Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) technology, today announced that CEO David Giljohann will present at the BTIG Virtual Biotechnology Conference on Monday, August 9, 2021 at 2:30pm ET.
  • BTIG hosted events are intended for prospective and existing BTIG clients only.
  • To listen to the live event, please contact your BTIG representative with interest.
  • Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases and other genetic disorders based on its proprietary Spherical Nucleic Acid, or SNA technology.

Stories of the Pandemic, mRNA Vaccines, Atoms, Planet Earth, and the Big Bang Come Alive for Children in Two 2021 Award-Winning Illustrated Children's STEM Books

Retrieved on: 
Wednesday, August 4, 2021
Branches of biology, Life sciences, Biology, RNA, Biotechnology, Nucleic acids, Molecular biology, Virus, DNA, RNA vaccine, Introduction to viruses

They learn in simple terms about the genetic code, DNA, cell biology, viruses, bacteria, vaccines, RNA, and messenger RNA (mRNA).

Key Points: 
  • They learn in simple terms about the genetic code, DNA, cell biology, viruses, bacteria, vaccines, RNA, and messenger RNA (mRNA).
  • Our COVID-19-Coronavirus LEARNING PAGEincludes eight illustrated short stories, video links, lesson plans, and questions.
  • LEARNING PAGES for Atoms, Planet Earth, and The Universe are also available on the Educators tab of TheStardustMystery.com web site.
  • "There are so many wonderful and exciting stories in science to tell," said Dr. Peter Solomon, CEO of TheBeamer LLC.

TriLink BioTechnologies® Extends Global Support of Covid-19 Vaccine Development into APAC Region with the Chula Vaccine Research Center (Chula VRC), Bangkok

Retrieved on: 
Monday, August 2, 2021
Nucleic acids, COVID-19, COVID-19 vaccines, Clinical trials, Branches of biology, RNA vaccines, Medical research, BioNTech, COVID-19 vaccine, Vaccine, Messenger RNA, Operation Warp Speed

TriLink will also continue to support manufacturing of the vaccine through the use of its CleanCap mRNA capping technology for mRNA synthesis.

Key Points: 
  • TriLink will also continue to support manufacturing of the vaccine through the use of its CleanCap mRNA capping technology for mRNA synthesis.
  • The ChulaCov19 mRNA Covid-19 Vaccine Development Program aims to expand access to an mRNA Covid-19 vaccine in Thailand and other low-to-middle-income countries (LMICs) in Asia.
  • Kiat Ruxrungtham, Director, ChulaVRC Covid-19 Vaccine Development Program, stated: It is our great pleasure to partner with the TriLink team in fighting this pandemic.
  • TriLink continues to expand its cGMP and general manufacturing capacity at its new global headquarters to support mRNA, oligonucleotide & plasmid therapeutic, vaccine and diagnostic customers.

Moderna Announces First Participant Dosed in Phase 1 Study of Its IL-2 mRNA Therapeutic

Retrieved on: 
Monday, August 2, 2021
Research, Infectious diseases, Genetics, Clinical trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Nucleic acids, RNA, Medical research, COVID-19 vaccines, Clinical trials, Moderna, Messenger RNA, RNA vaccine, Uğur Şahin, mRNA-6231, Moderna, MRNA-6231, MODERNA

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the first participant has been dosed in the Phase 1 study of mRNA-6231, the Companys mRNA-encoded IL-2 modified for the expansion of regulatory T cells.

Key Points: 
  • Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the first participant has been dosed in the Phase 1 study of mRNA-6231, the Companys mRNA-encoded IL-2 modified for the expansion of regulatory T cells.
  • This is our first mRNA autoimmune candidate, and the first to be subcutaneously administered.
  • Today marks another important step in our mission to deliver on the promise of mRNA to help patients across diseases.
  • Moderna now has active clinic programs in five different therapeutic areas: infectious disease, oncology, cardiovascular, rare disease and autoimmune disease.

Arcturus Therapeutics Collaborates with Vingroup to Establish Manufacturing Facility in Vietnam for Arcturus’ Investigational mRNA Vaccines for COVID-19

Retrieved on: 
Monday, August 2, 2021
Health, Infectious diseases, Manufacturing, Genetics, Other Manufacturing, Pharmaceutical, Nucleic acids, COVID-19 vaccines, Clinical trials, RNA vaccines, Moderna COVID-19 vaccine, COVID-19 vaccine, Vaccine, Messenger RNA, Arcturus Therapeutics, Arcturus COVID-19 vaccine

Arcturus will provide Vinbiocare with an exclusive license to manufacture the vaccines in Vietnam at the facility solely for distribution in Vietnam.

Key Points: 
  • Arcturus will provide Vinbiocare with an exclusive license to manufacture the vaccines in Vietnam at the facility solely for distribution in Vietnam.
  • The license and technology transfer applies toward drug product manufacturing but not toward mRNA drug substance manufacturing.
  • Vinbiocare will also pay for mRNA drug substance supplied by Arcturus and royalties on vaccines produced at the Facility.
  • Arcturus investigational COVID-19 vaccines utilize Arcturus self-transcribing and replicating (STARR) mRNA technology, and the STARR mRNA is delivered with Arcturuss lipid-mediated delivery system called LUNAR delivery system.

Arcturus Therapeutics to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 9, 2021

Retrieved on: 
Monday, July 26, 2021
Research, Infectious diseases, Genetics, Clinical trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Nucleic acids, Branches of biology, RNA, Biology, Molecular biology, Gene expression, Biotechnology, DNA, RNA therapeutics, Sense, Arcturus Therapeutics

Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.

Key Points: 
  • Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.
  • Arcturus technologies are covered by its extensive patent portfolio (222 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries).
  • In addition, please connect with us on Twitter and LinkedIn .
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20210726005727/en/

Pharma and Biotech to Highly Invest in RNA Therapeutics to Expedite Research & Development across the Globe

Retrieved on: 
Thursday, July 22, 2021
Nucleic acids, RNA, Branches of biology, Molecular biology, Biotechnology, RNA vaccine, RNA therapeutics, Small interfering RNA, Sense, Sirna, Messenger RNA, Arcturus Therapeutics

SANTA CLARA, Calif., July 22, 2021 /PRNewswire/ -- Frost & Sullivan's recent analysis, Global RNA Therapeutics: Technology Growth Opportunities, reveals that ribonucleic acid (RNA) therapeutics is poised to gain momentum in the next few years and can potentially be applied to a wide variety of disease interventions. Additionally, the growth opportunities exposed by the initial commercialization of mRNA vaccines, antisense oligonucleotides (ASOs) and short interfering RNA (siRNA)-based therapeutics are further attracting pharmaceutical and biotechnology companies to invest in this space and expedite research and development (R&D). 

Key Points: 
  • Additionally, the growth opportunities exposed by the initial commercialization of mRNA vaccines, antisense oligonucleotides (ASOs) and short interfering RNA (siRNA)-based therapeutics are further attracting pharmaceutical and biotechnology companies to invest in this space and expedite research and development (R&D).
  • As a result, academic labs and small biotech companies are accelerating RNA therapeutics research, alongside Tier 1 biopharmaceutical companies."
  • Hence, RNA therapeutics investment has a better chance of commercial success and enables better returns in less time for market participants.
  • mRNA vaccines and active participation of big pharmaceutical companies: Currently, RNA therapeutics is one of the fastest and most promising approaches in biological therapeutics.

Pharma and Biotech to Highly Invest in RNA Therapeutics to Expedite Research & Development across the Globe

Retrieved on: 
Thursday, July 22, 2021
Nucleic acids, RNA, Branches of biology, Molecular biology, Biotechnology, RNA vaccine, RNA therapeutics, Small interfering RNA, Sense, Sirna, Messenger RNA, Arcturus Therapeutics

SANTA CLARA, Calif., July 22, 2021 /PRNewswire/ -- Frost & Sullivan's recent analysis, Global RNA Therapeutics: Technology Growth Opportunities, reveals that ribonucleic acid (RNA) therapeutics is poised to gain momentum in the next few years and can potentially be applied to a wide variety of disease interventions. Additionally, the growth opportunities exposed by the initial commercialization of mRNA vaccines, antisense oligonucleotides (ASOs) and short interfering RNA (siRNA)-based therapeutics are further attracting pharmaceutical and biotechnology companies to invest in this space and expedite research and development (R&D). 

Key Points: 
  • Additionally, the growth opportunities exposed by the initial commercialization of mRNA vaccines, antisense oligonucleotides (ASOs) and short interfering RNA (siRNA)-based therapeutics are further attracting pharmaceutical and biotechnology companies to invest in this space and expedite research and development (R&D).
  • As a result, academic labs and small biotech companies are accelerating RNA therapeutics research, alongside Tier 1 biopharmaceutical companies."
  • Hence, RNA therapeutics investment has a better chance of commercial success and enables better returns in less time for market participants.
  • mRNA vaccines and active participation of big pharmaceutical companies: Currently, RNA therapeutics is one of the fastest and most promising approaches in biological therapeutics.

Codex DNA Announces Licensing and Supply Deal with TriLink Biotechnologies for CleanCap® mRNA Capping Technology

Retrieved on: 
Wednesday, July 21, 2021
Nucleic acids, Branches of biology, Biology, RNA, DNA, Gene expression, Molecular genetics, Protein biosynthesis, Messenger RNA, Gibson assembly

Codex DNA will integrate the mRNA capping technology into its suite of automated mRNA synthesis kits for the BioXp system as well as within the companys BioFoundry Services offering.

Key Points: 
  • Codex DNA will integrate the mRNA capping technology into its suite of automated mRNA synthesis kits for the BioXp system as well as within the companys BioFoundry Services offering.
  • Codex DNAs new BioXp small-scale mRNA synthesis kit with CleanCap reagents is expected to overcome many of these challenges by increasing the yields and productivity of synthetically designed mRNA products.
  • The TriLink CleanCap technology is the current industry standard for capping mRNA and this collaboration enables us to expand the range of applications for our award-winning BioXp system, said Todd R. Nelson, PhD, CEO of Codex DNA.
  • Codex DNA, the Codex DNA logo, Gibson Assembly, and BioXp are trademarks of Codex DNA Inc.